Lytix Biopharma Announces Regulatory Approval by Swedish Authorities to Commence Phase I/IIa Clinical Trial with LytixarTM (LTX-109) in MRSA  
5/24/2010 10:47:24 AM

TROMSØ & OSLO, Norway--(BUSINESS WIRE)--The Norwegian pharmaceutical company Lytix Biopharma AS today announces the approval by the Swedish Medical Products Agency (”Läkemedelverket”) to commence a Phase I/IIa clinical trial with LytixarTM (LTX-109) for nasal decolonisation of MRSA (methicillin-resistant Staphylococcus aureus).